Analysts downgraded uniQure N.V. after the U.S. Food and Drug Administration signalled it would require a sham surgery-controlled Phase 3 trial for the company’s Huntington’s disease therapy, dimming ...
Intellia is now able to continue both Phase III trials of nex-z. Credit: Piotr Swat / Shutterstock.com (Piotr Swat / Shutterstock.com) The US Food and Drug Administration (FDA) has released the ...
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AßOs) for the treatment of Alzheimer ...
Enter a world of splendor and romance, of eye-popping excess, of glitz, grandeur and glory! A world where Bohemians and aristocrats rub elbows and revel in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results